Persistence of chromosomal aberrations in blood lymphocytes 11 years after cessation of CMF therapy in a breast cancer patient

Cancer Letters

Volumn 107, Issue 1, 1996, Pages 1-3

  Udayakumar, A M ^a   Bhargava, M Krishna ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

5 fluorouracil; Breast cancer; Chromosomal aberrations; CMF therapy; Cyclophosphamide; Methotrexate

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; DRUG WITHDRAWAL; FEMALE; GENETIC STABILITY; HUMAN; HUMAN CELL; LYMPHOCYTE; PRIORITY JOURNAL; STEM CELL;

EID: 0030271660     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04313-3     Document Type: Article

References (17)

1. [1] Yunis, J.J. (1983) The chromosomal basis of human neoplasia. Science, 221, 227-236.
2. [2] Mitelman, F. (1984) Restricted number of chromosomal regions implicated in aetiology of human cancer and leukemia. Nature, 310, 325-327.
3. [3] Gebhart, E., Losing, J. and Wopfner, F. (1980) Chromosome studies on lymphocytes of patients under cytostatic therapy. I. Conventional chromosome studies in cytostatic interval therapy. Hum. Genet., 55, 53-63.
4. [4] Lambert, B., Holmberg, K. and Einhorn, N. (1984) Persistence of chromosome rearrangements in peripheral lymphocytes from patients treated with melphalan for ovarian carcinoma. Hum. Genet., 67, 94-98.
5. [5] Lambert, B., Holmberg, K. and Einhorn, N. (1986) Chromosomal damage and second malignancy in patients treated with melphalan. In: Carcinogenicity of Alkylating Cytostatic Drugs, pp. 147-160. Editors: D. Schmahl and J.M. Kaldor. IARC, Lyon, No. 78.
6. [6] Gundy, S., Baki, M., Bodrogi, I. and Czeizel, A. (1990) Persistence of chromosomal aberrations in blood lymphocytes of testicular cancer patients. Oncology, 47, 410-414.
7. [7] Schinzel, A. and Schmid, W. (1976) Lymphocyte chromosome studies in humans exposed to chemical mutagens. The validity of the method in 67 patients under cytostatic therapy. Mutat. Res., 40, 139-166.
8. [8] Weisburger, E. (1977) Bioassay programme for carcinogenic hazard of cancer chemotherapeutic agents. Cancer, 40, 1935-1949.
9. [9] Harris, C.C. (1979) A delayed complication of cancer therapy: cancer. J. Natl. Cancer Inst., 63, 275-277.
10. [10] Klein, G. (1981) The role of gene dosage and genetic transpositions in carcinogenesis. Nature, 294, 313-318.
11. [11] Radman, M., Jeggo, P. and Wagner, R. (1982) Chromosomal rearrangements and carcinogenesis. Mutat. Res., 98, 249-264.
12. [12] Rowley, J.D. (1983) Human oncogene location and chromosome aberrations. Nature, 301, 290-291.
13. [13] Sandberg, A.A. (1990) The Chromosomes in Human Cancer and Leukemia, 2nd edn. Elsevier, New York.
14. [14] Louis, C.J. (1978) Tumors: Basic Principles and Clinical Aspects, pp. 132-133. Churchill Livingstone, Edinburgh.
15. [15] Botnick, L.E., Hannon, E.C. and Hellman, S. (1976) Limited proliferation of stem cells surviving alkylating agents. Nature, 262, 68-70.
16. [16] Buckton, K.E., Smith, P.G. and Court Brown, W.M. (1967) The estimation of lymphocyte life span from studies on males treated with X-rays for ankylosing spondylitis. In: Human Radiation Cytogenetics, pp. 106-114. Editors: H.J. Evans, W.M. Court Brown and A.S. McLean. North Holland, Amsterdam.
17. [17] Hass, J.F., Kittelmann, B., Mehnert, W.H., Staneezek, W., Mohner, M., Kaldor, J.M. and Day, N.E. (1987) Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br. J. Cancer, 55, 213-218.